Literature DB >> 22146883

SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.

Hsieh-Cheng Chen1, Yung-Ming Jeng, Ray-Hwang Yuan, Hey-Chi Hsu, Yu-Ling Chen.   

Abstract

BACKGROUND: SIRT1 is a NAD+-dependent deacetylase that plays crucial roles in many biological processes, including stress response, apoptosis, cellular metabolism, adaptation to calorie restriction, aging, and tumorigenesis. The purpose of this study is to elucidate the clinicopathological and functional significance of SIRT1 expression in hepatocellular carcinoma (HCC).
METHODS: SIRT1 expression in HCC was determined by immunohistochemical staining. The results were correlated with clinicopathological parameters. SIRT1 was overexpressed in HCC cell line SK-Hep1 to study its role in tumorigenesis and resistance to chemotherapy.
RESULTS: SIRT1 was overexpressed in 95 of 172 HCCs (55%). SIRT1 overexpression was associated with higher α-fetoprotein level, higher tumor grade, and absence of β-catenin mutation. SIRT1 expression predicted poor long-term survival for patients with resected HCC. The elevated SIRT1 protein level in HCC was not attributable to the elevation of mRNA level. The half-life of SIRT1 protein was longer in cell lines with higher expression of SIRT1. We further demonstrated that SIRT1 was degraded by the 26S proteasome in an ubiquitin-dependent manner. Overexpression of SIRT1 promoted tumorigenesis and resistance to chemotherapeutical agent and sorafenib.
CONCLUSIONS: SIRT1 is an oncogenic protein for HCC and is a predictor of worse outcome after surgical resection of HCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22146883     DOI: 10.1245/s10434-011-2159-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  78 in total

1.  Silent information regulator 1 (SIRT1) promotes the migration and proliferation of endothelial progenitor cells through the PI3K/Akt/eNOS signaling pathway.

Authors:  Wei Li; Dayong Du; Hang Wang; Yang Liu; Xiaohui Lai; Feng Jiang; Dong Chen; Yanbin Zhang; Jiaxin Zong; Yuntian Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.

Authors:  Koji Miyahara; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Inhibition of diethylnitrosamine-initiated alcohol-promoted hepatic inflammation and precancerous lesions by flavonoid luteolin is associated with increased sirtuin 1 activity in mice.

Authors:  Bruna Paola Murino Rafacho; Camilla Peach Stice; Chun Liu; Andrew S Greenberg; Lynne M Ausman; Xiang-Dong Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

Review 4.  Dysregulated glycolysis as an oncogenic event.

Authors:  Takumi Mikawa; Matilde E LLeonart; Akifumi Takaori-Kondo; Nobuya Inagaki; Masayuki Yokode; Hiroshi Kondoh
Journal:  Cell Mol Life Sci       Date:  2015-01-22       Impact factor: 9.261

5.  Higher expression of SIRT1 induced resistance of esophageal squamous cell carcinoma cells to cisplatin.

Authors:  Bin Cao; Qintong Shi; Wengong Wang
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

6.  The expression and correlation of SIRT1 and Phospho-SIRT1 in colorectal cancer.

Authors:  Xianzhen Zhang; Suiqin Chen; Meili Cheng; Fangli Cao; Yufeng Cheng
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 7.  Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target.

Authors:  Yuting Wu; Xiaoming Meng; Cheng Huang; Jun Li
Journal:  Tumour Biol       Date:  2015-05-01

Review 8.  Mechanistic understanding of β-cryptoxanthin and lycopene in cancer prevention in animal models.

Authors:  Ji Ye Lim; Xiang-Dong Wang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-02-05       Impact factor: 4.698

9.  Clinicopathological significance of SIRT1 expression in colorectal adenocarcinoma.

Authors:  Liang Lv; Zhanlong Shen; Jizhun Zhang; Hui Zhang; Jianqiang Dong; Yichao Yan; Fangfang Liu; Kewei Jiang; Yingjiang Ye; Shan Wang
Journal:  Med Oncol       Date:  2014-05-10       Impact factor: 3.064

10.  Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

Authors:  Josiah Cox; Steven Weinman
Journal:  Hepat Oncol       Date:  2016-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.